Ownership history in CITADEL ADVISORS LLC Β· 3 quarters on record
This page tracks every 13F SEC filing in which CITADEL ADVISORS LLC reported a position in ADVANCED BIOMED INC (ADVB). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π CITADEL ADVISORS LLC underperformed the S&P 500 by β274.1% annually on this ADVB position. Average cost basis: $16.22. Maximum drawdown during holding period: β88.6%.
β Significantly underperformed the S&P 500 by 274.1% ann.
2 quarters analyzed
Best entry: $8.96 (2025 Q3) Β· Worst: $78.40 (2025 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 0 trims. Bought during 2 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size